Abstract
Thirty-one consecutive patients with advanced epithelial ovarian cancer entered a phase II study with cisplatin and etoposide combination chemotherapy. None of them had received prior chemotherapy or radiotherapy. Most patients had advanced (88%) or far advanced (61%) disease. All 31 patients are evaluable for toxicity which was significant and led to removal of five (16%) patients from the study. Of the 23 patients evaluable for response there were four clinical complete (CR) and eight partial (PR) responders for a total clinical response rate of 52% of evaluable patients and 39% of all patients. Eight patients (four clinical CR and four good PR) have undergone second look laparotomy with pathological CR in one of the clinical CR patients. Median survival time for responders and non-responders is 19 and 8 months respectively. The results obtained appear to be inferior to other cisplatin based combinations. Although this could be attributed to the unusually high proportion of patients with bulky disease and stage IV patients, we feel that the study suggests that etoposide did not add any benefits for this patient population to cisplatin as a single agent.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Copeland L. J., Gershenson D. M. Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy. Obstet Gynecol. 1986 Dec;68(6):873–874. [PubMed] [Google Scholar]
- Edwards C. L., Herson J., Gershenson D. M., Copeland L. J., Wharton J. T. A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer. Gynecol Oncol. 1983 Apr;15(2):261–277. doi: 10.1016/0090-8258(83)90082-3. [DOI] [PubMed] [Google Scholar]
- Hainsworth J. D., Williams S. D., Einhorn L. H., Birch R., Greco F. A. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. J Clin Oncol. 1985 May;3(5):666–671. doi: 10.1200/JCO.1985.3.5.666. [DOI] [PubMed] [Google Scholar]
- Ho A. G., Beller U., Speyer J. L., Colombo N., Wernz J., Beckman E. M. A reassessment of the role of second-look laparotomy in advanced ovarian cancer. J Clin Oncol. 1987 Sep;5(9):1316–1321. doi: 10.1200/JCO.1987.5.9.1316. [DOI] [PubMed] [Google Scholar]
- Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Vriesendorp R., Kooyman C. D., van Lindert A. C., Hamerlynck J. V., van Lent M., van Houwelingen J. C. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet. 1984 Sep 15;2(8403):594–600. doi: 10.1016/s0140-6736(84)90594-4. [DOI] [PubMed] [Google Scholar]
- Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
- Rosenfeld C. S., Broder L. E. Cisplatin-induced autonomic neuropathy. Cancer Treat Rep. 1984 Apr;68(4):659–660. [PubMed] [Google Scholar]
- Thigpen T., Blessing J. A. Current therapy of ovarian carcinoma: an overview. Semin Oncol. 1985 Sep;12(3 Suppl 4):47–52. [PubMed] [Google Scholar]